Comparing Gold Nanoparticle and Magnetite Nanoparticle Penetration into Platelet Rich Plasma Clots
Mentor 1
Julie Oliver
Start Date
1-5-2020 12:00 AM
Description
We are investigating alternative treatments for patients with ischemic stroke that are unable to receive tissue plasminogen activator (tPA) due to bleeding risk. We proposed that targeting activated platelets rather than fibrin in occlusive thrombi for magnetically induced hyperthermia could provide treatment for ischemic stroke with minimal risk of bleeding. Since synthesizing gold-coated magnetite nanoparticles (FGN-cAu-Fe3O4) is not a robust procedure, previous work used the robust fibrinogen-conjugated gold nanoparticles (FGN-cAu18) model to examine the nanoparticle penetration into clots. The goal of this research is to inspect whether FGN-cAu-Fe3O4 and FGN-cAu18 of approximately the same diameter show differences in their ability to penetrate and concentrate in clots during labeling. We hypothesize that FGN-cAu-Fe3O4 will access the interior of platelet-rich plasma (PRP) clots to the same extent as FGN-cAu18. To test that hypothesis, PRP was clotted in vitro using low and high thrombin concentrations, followed by labeling with either FGN-cAu18 or FGN-cAu-Fe3O4. Frozen cross-sections were treated with silver enhancement and analyzed by light microscopy. As expected, FGN-cAu18 and FGN-cAu-Fe3O4 produced several similar results. First, the degree of nanoparticle penetration and concentration inside PRP clots are consistent between both types of nanoparticles. Second, the extent of nanoparticle penetration was inversely related to the thrombin concentration, with high thrombin concentration resulting in reduced nanoparticle penetration. Third, more nanoparticles deposit at the clot periphery and their concentration is reduced at the center of clots. These results confirm that FGN-cAu18 can be a representative model for FGN-cAu-Fe3O4 in term of studying the nanoparticle penetration into clots.
Comparing Gold Nanoparticle and Magnetite Nanoparticle Penetration into Platelet Rich Plasma Clots
We are investigating alternative treatments for patients with ischemic stroke that are unable to receive tissue plasminogen activator (tPA) due to bleeding risk. We proposed that targeting activated platelets rather than fibrin in occlusive thrombi for magnetically induced hyperthermia could provide treatment for ischemic stroke with minimal risk of bleeding. Since synthesizing gold-coated magnetite nanoparticles (FGN-cAu-Fe3O4) is not a robust procedure, previous work used the robust fibrinogen-conjugated gold nanoparticles (FGN-cAu18) model to examine the nanoparticle penetration into clots. The goal of this research is to inspect whether FGN-cAu-Fe3O4 and FGN-cAu18 of approximately the same diameter show differences in their ability to penetrate and concentrate in clots during labeling. We hypothesize that FGN-cAu-Fe3O4 will access the interior of platelet-rich plasma (PRP) clots to the same extent as FGN-cAu18. To test that hypothesis, PRP was clotted in vitro using low and high thrombin concentrations, followed by labeling with either FGN-cAu18 or FGN-cAu-Fe3O4. Frozen cross-sections were treated with silver enhancement and analyzed by light microscopy. As expected, FGN-cAu18 and FGN-cAu-Fe3O4 produced several similar results. First, the degree of nanoparticle penetration and concentration inside PRP clots are consistent between both types of nanoparticles. Second, the extent of nanoparticle penetration was inversely related to the thrombin concentration, with high thrombin concentration resulting in reduced nanoparticle penetration. Third, more nanoparticles deposit at the clot periphery and their concentration is reduced at the center of clots. These results confirm that FGN-cAu18 can be a representative model for FGN-cAu-Fe3O4 in term of studying the nanoparticle penetration into clots.
